Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Unorthodox Inhibitors of HIV Protease: Looking Beyond Active-site-directed Peptidomimetics

Author(s): Jiri Schimer and Jan Konvalinka

Volume 20, Issue 21, 2014

Page: [3389 - 3397] Pages: 9

DOI: 10.2174/13816128113199990634

Price: $65

Abstract

HIV protease (PR) is a key target for antiviral drugs, and HIV protease inhibitors (PIs) are a prime example of successful structure-based drug design. PIs show clear therapeutic benefits, but their efficacy can be compromised by poor bioavailabilitity, unwanted side effects, and most importantly, development of antiviral drug resistance. Therefore, the quest for novel, highly active compounds with improved resistance profiles, better pharmacokinetic properties, and fewer adverse effects continues. In particular, the problem of cross-resistance could be circumvented by identifying novel compounds that show different binding modes to HIV PR than the current clinical inhibitors.

Keywords: Proteinase, proteolytic processing, virostatic, rational drug design, resistance development.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy